Boehringer's Pradaxa- First Pill to Replace Warfarin

by Dr. Trupti Shirole on  November 2, 2011 at 11:48 PM Drug News
RSS Email Print This Page Comment
The National Institute of Health and Clinical Excellence (NICE), UK has recommended
Boehringer Ingelheim's new anti-coagulant Pradaxa (dabigatran) for the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF).
 Boehringer's Pradaxa- First Pill to Replace Warfarin
Boehringer's Pradaxa- First Pill to Replace Warfarin

This oral medicine is an alternative to Warfarin which has been the standard blood thinner since mid 1950. Unlike Warfarin; dabigatran does not require frequent blood tests to monitor treatment. This is a significant benefit for many patients with AF.

Boehringer beat Xarelto, from Bayer AG (BAYN.XE) and Johnson & Johnson (JNJ), and Eliquis from Bristol-Myers Squibb Co.(BMY) and Pfizer Inc. (PFE) to become the first pill to replace warfarin.

However the final guidance on Pradaxa will be issued by NICE only in the next month. 

Source: Medindia

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Vasectomy Anticoagulants Deep Vein Thrombosis Pulmonary Embolism 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive